SBIR/STTR Research Award
IGF::OT::IGF: FY13: Phenotypic Screening of Smoking Cessation Drugs, N43DA-13-7
Award amount
$338,884Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AFASCI, INC.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- UGMEBNM4WSL6
- Solicitation number
- Not reported
- Topic code
- NIDA
Research abstract
Under this Small Business Innovation Research (SBIR) Phase I project, Research Topic 149, the Contractor shall develop predictive in vivo screening systems for phenotypic drug discovery for smoking cessation. The Contractor shall accomplish this throughthe following objectives: Objective 1- Evaluate a battery of tests aimed at examining various components of nicotine addiction to be used for phenotypic drug discovery and development of smoking cessation medications. Objective 2- Phenotypically profilefour FDA approved smoking cessation drugs (varenicline, bupropion, clonidine and nortriptyline, each tested at three doses) and two controls (positive drug at an appropriate dose and negative with vehicle) using the behavioral tests/assays validated inObjective 1. PUBLIC HEALTH RELEVANCE
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Developing a novel treatment of cocaine use disorder using an IND dual inhibitor of Cav3 channel and soluble epoxide hydrolase
- Accelerating the non-opioid analgesic AFA-281 clinical development with TABA-supported business development
- Development of a Novel Medication for Alcohol Use Disorder with an Active IND Dual Inhibitor of T-Type Calcium Channel and Soluble Epoxide Hydrolase
- Development of a Next Generation Visual Performance Assessment System for Rodents
- IND-enabling studies on novel Cav3 T-channel modulators for treatment of neuropathic pain
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)
Research funding history
27 SBIR/STTR records share this UEI (2003–2023). Reported award amounts total $22,071,530. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services